Trazodone Starting Dose for Insomnia
The most recent and highest-quality evidence advises AGAINST using trazodone as first-line treatment for insomnia, but if prescribed despite this recommendation, start with 25-50 mg at bedtime.
Current Guideline Recommendations
The 2020 VA/DoD guidelines explicitly recommend AGAINST trazodone for chronic insomnia disorder 1. This represents the most recent authoritative guidance and supersedes older recommendations. The systematic review supporting this guideline found that trazodone (50-150 mg) showed no differences in sleep efficiency or discontinuation rates compared to placebo, and while subjective sleep quality improved, there were no improvements in sleep onset latency, total sleep time, or wake after sleep onset 1.
Similarly, the 2017 American Academy of Sleep Medicine clinical practice guideline suggests that clinicians NOT use trazodone for sleep onset or sleep maintenance insomnia, based on trials of 50 mg doses 2. This is a formal weak recommendation against its use.
Dosing Information When Prescribed Off-Label
Despite guideline recommendations against its use, trazodone remains widely prescribed for insomnia. When clinicians choose to prescribe it (typically for comorbid depression or treatment failures):
Starting Dose
- 25-50 mg at bedtime is the appropriate starting dose for insomnia 3, 4
- The palliative care guideline specifically recommends 25-100 mg PO at bedtime 3
- Studies have evaluated doses ranging from 50-150 mg 1
Dosing Context from FDA Labeling
The FDA-approved labeling for trazodone is for depression, not insomnia 5. For depression, the initial dose is 150 mg/day in divided doses, with increases of 50 mg every 3-4 days up to 400 mg/day for outpatients 5. However, insomnia treatment uses substantially lower doses than antidepressant dosing.
Administration Guidelines
- Take shortly after a meal or light snack to optimize absorption 5
- Administer as a single dose at bedtime rather than divided doses 6
- Can be taken as whole tablet or half tablet along score line 5
Clinical Reasoning for the Recommendation Against Use
The evidence hierarchy clearly shows:
Lack of efficacy: No objective improvements in key sleep parameters (sleep efficiency, sleep onset latency, total sleep time, wake after sleep onset) compared to placebo 1
Adverse effect profile outweighs benefits: Known risks include:
Better alternatives exist: Nonbenzodiazepine BZRAs (zolpidem, eszopiclone, zaleplon) and low-dose doxepin have stronger evidence for efficacy 1, 2
When Trazodone Might Be Considered
The older 2008 AASM guideline positioned trazodone as a third-line option after BZRAs and only when accompanied by comorbid depression or other treatment failures 10. Specific scenarios where it may be considered:
- Comorbid depression with insomnia (though low doses are inadequate for treating major depression) 10
- History of substance abuse where controlled substances are contraindicated
- Respiratory conditions (sleep apnea, COPD) where benzodiazepines pose risks 10
- Palliative care settings where multiple symptom management is needed 3
Critical Safety Warnings
- Cardiac monitoring required in patients with preexisting cardiac disease, QT prolongation, or arrhythmia history 5
- Avoid in elderly due to fall risk from orthostatic hypotension 5
- Counsel male patients about priapism risk: seek emergency care if erection lasts >4 hours 5
- Screen for bipolar disorder before initiating, as with all antidepressants 5
- Monitor for serotonin syndrome if combined with other serotonergic drugs 5
Bottom Line
Trazodone should not be first-line therapy for insomnia based on 2020 guidelines 1, 2. If prescribed off-label despite this recommendation, start with 25-50 mg at bedtime, taken with food. Reserve for patients with comorbid depression or when FDA-approved hypnotics are contraindicated. The widespread use of trazodone for insomnia reflects clinical practice patterns that are not supported by the highest quality evidence prioritizing morbidity, mortality, and quality of life outcomes.